Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
|
Aspira Women's Health Inc. (VRML)
|
Add to portfolio |
|
|
|
| Price: |
$6.32
| | Metrics |
| OS: |
10.2
|
M
| |
|
|
| Market cap: |
$64.5
|
M
| |
|
|
|
Net cash:
|
$4.25
|
M
| |
$0.42
|
per share
|
|
EV:
|
$60.2
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($24.5)
|
M
| |
|
|
| EPS |
($1.09)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 8.2 | 6.8 | 4.7 | 4.5 | 3.1 | 3.1 | 2.6 | 2.2 |
| Revenue growth | 20.1% | 46.5% | 2.5% | 48.6% | -2.2% | 18.1% | 21.4% | -13.6% |
| Cost of goods sold | 3.9 | 3.8 | 3.4 | 3.3 | 3.1 | 2.9 | 2.7 | 2.3 |
| Gross profit | 4.3 | 3.1 | 1.2 | 1.2 | -0.1 | 0.2 | -0.1 | -0.1 |
| Gross margin | 52.8% | 45.0% | 26.6% | 26.3% | -2.9% | 6.6% | -2.1% | -6.1% |
| Sales and marketing | 14.9 | 17.1 | 8.8 | 9.6 | 5.6 | 4.3 | 6.8 | 9.8 |
| Research and development | 6.0 | | | 1.0 | 0.6 | 0.8 | 2.2 | 3.8 |
| General and administrative | 16.2 | | | 5.8 | 5.1 | 5.5 | 5.9 | 5.5 |
| EBIT | -32.8 | -32.6 | -18.0 | -15.3 | -11.3 | -10.4 | -15.0 | -19.2 |
| EBIT margin | -400.4% | -478.5% | -386.6% | -336.7% | -371.2% | -334.5% | -566.0% | -884.2% |
| Pre-tax income | -27.2 | 31.7 | 17.9 | 15.2 | -11.4 | -10.5 | -15.0 | -19.1 |
| Income taxes | 0.0 | 63.3 | 35.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 200.0% | 200.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -27.2 | -31.7 | -17.9 | -15.2 | -11.4 | -11.4 | -15.0 | -19.1 |
| Net margin | -332.0% | -464.8% | -385.0% | -335.8% | -372.5% | -366.5% | -566.5% | -878.0% |
| |
| Diluted EPS | ($0.23) | ($0.28) | ($0.18) | ($0.18) | ($0.16) | ($0.20) | ($0.29) | ($0.41) |
| Shares outstanding (diluted) | 116.5 | 111.2 | 100.7 | 86.6 | 70.1 | 56.9 | 52.2 | 47.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|